Identification of Subclinical Myocardial Dysfunction in Breast Cancer Patients with Metabolic Syndrome after Cancer-Related Comprehensive Therapy

<div>LVEF (a) and GLS (b) in breast cancer patients with metabolic syndrome (MetSyn) and breast cancer patients without metabolic syndrome (MetSyn) after cancer-related therapy.</div>

Cardiology Research and Practice

fig2

Figure 2

Figure 2: Identification of Subclinical Myocardial Dysfunction in Breast Cancer Patients with Metabolic Syndrome after Cancer-Related Comprehensive Therapy 

Figure 2 | Identification of Subclinical Myocardial Dysfunction in Breast Cancer Patients with Metabolic Syndrome after Cancer-Related Comprehensive Therapy 